A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Status:
Terminated
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, open-label, extension trial designed to evaluate the long term safety and
efficacy over 3 months of TNX-102 SL tablets taken daily at bedtime for the treatment of
Fibromyalgia (FM). Patients recruits into this trial are those who have successfully
completed the double-blind studies; TNX-CY-F301 and TNX-CY-F302. Anticipated start for
TNX-CY-F302 is for March 2016.
Patients will not be made aware of the therapy they received during the double-blind study.